BTIG Maintains Buy on AtriCure, Raises Price Target to $70
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $63 to $70.
BTIG analyst Marie Thibault maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $63 to $70.